News

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.
The IRA’s impact on biosimilar development and adoption. An analysis from IQVIA found that between 2017 and 2021 the U.S. spent $260 billion on originator biologics, 2 the reference products on ...
Biosimilar products are highly similar, ... 34% didn’t know that biosimilars don’t necessarily have the same chemical structure and manufacturing process as the reference product, ...
The biosimilars market is a new sector emerging from the success of the biologics industry. As of July 2022, there were 36 biosimilars approved for use in the US1 and 73 approved for the European ...
The House Ways and Means Committee heard testimony on hindrances to the expansion of use of biosimilars, medications close in structure and function to a patented biologic medicine. Witnesses at the ...
With the global market for biologics estimated at $382 billion just last year, and a projected global drug spend of close to $1.5 trillion by 2027, the landscape is ripe for biosimilars to help ...
Reflecting on the biosimilar landscape Biosimilar medicines are central to our purpose at Celltrion Healthcare. Put simply, a biosimilar is a biological medicine that is highly similar to another ...
Item 1 of 2 Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo ...
Biosimilars have shown to be just as effective as original brand name medications in ... (TNF alpha), but they may differ in structure or means of administration. Infliximab (Remicade ...
Serve You Rx, a pharmacy benefit manager, has added two recently approved biosimilars to Stelara to its formulary, the company announced Thursday. Milwaukee, Wisconsin-based Serve You Rx is an ...
The European Commission's pharmaceutical reform would improve access to cheaper biosimilar medicines and speed up the time it takes to access the market. Connie Ziegler was diagnosed with ...